CMPX (Compass Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by CMPX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-29 | Neil Lerner | Chief Accounting Officer | A | — | — |
| 2026-04-29 | Jonathan Anderman | General Counsel | A | — | — |
| 2026-02-10 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-01-12 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2026-01-05 | Cynthia Sirard | Chief Medical Officer | A | — | — |
| 2026-01-05 | CARL L GORDON | Director | A | — | — |
| 2026-01-05 | RICHARD S LINDAHL | Director | A | — | — |
| 2026-01-05 | Jonathan Anderman | General Counsel | A | — | — |
| 2026-01-05 | MARY ANN GRAY | Director | A | — | — |
| 2026-01-05 | Arjun Prasad | Chief Commercial Officer | A | — | — |
| 2026-01-05 | Neil Lerner | Chief Accounting Officer | A | — | — |
| 2026-01-05 | Barry Shin | CFO | A | — | — |
| 2026-01-05 | Thomas J. Schuetz | CEO | A | — | — |
| 2026-01-05 | James P Boylan | Director | A | — | — |
| 2026-01-05 | Ellen Chiniara | Director | A | — | — |
| 2026-01-05 | Philip Ferneau | Director | A | — | — |
| 2025-11-18 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2025-05-27 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2025-04-11 | OrbiMed Capital GP VI LLC | Director | Sell | — | — |
| 2025-04-11 | CARL L GORDON | Director | Sell | — | — |
| 2025-04-08 | Neil Lerner | CHIEF ACCOUNTING OFFICER | Buy | — | — |
| 2025-04-08 | Jonathan Anderman | Gen Counsel & Corporate Sec | Buy | — | — |
| 2025-02-13 | James P Boylan | Director | A | — | — |
| 2025-02-13 | Jonathan Anderman | Sr VP, Gen Counsel & Corp Sec | A | — | — |
| 2025-02-13 | Barry Shin | CFO | A | — | — |
| 2025-02-13 | Neil Lerner | SVP, CAO | A | — | — |
| 2025-02-13 | MARY ANN GRAY | Director | A | — | — |
| 2025-02-13 | Philip Ferneau | Director | A | — | — |
| 2025-02-13 | RICHARD S LINDAHL | Director | A | — | — |
| 2025-02-13 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-02-13 | CARL L GORDON | Director | A | — | — |
| 2025-02-13 | Ellen Chiniara | Director | A | — | — |
| 2025-02-11 | Thomas J. Schuetz | CEO | F | — | — |
| 2025-01-13 | Thomas J. Schuetz | CEO | F | — | — |
| 2024-12-10 | Barry Shin | CFO | A | — | — |
| 2024-08-14 | Jonathan Anderman | Sr VP, Gen Counsel & Corp Sec | A | — | — |
| 2024-03-11 | James P Boylan | Director | A | — | — |
| 2024-02-14 | MARY ANN GRAY | Director | A | — | — |
| 2024-02-14 | Ellen Chiniara | Director | A | — | — |
| 2024-02-14 | RICHARD S LINDAHL | Director | A | — | — |
| 2024-02-14 | Philip Ferneau | Director | A | — | — |
| 2024-02-14 | CARL L GORDON | Director | A | — | — |
| 2024-02-09 | Vered Bisker-Leib | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2024-02-09 | Thomas J. Schuetz | PRESIDENT | F | — | — |
| 2024-01-10 | Vered Bisker-Leib | Chief Executive Officer | A | — | — |
| 2024-01-10 | Thomas J. Schuetz | President of R&D | A | — | — |
| 2023-11-21 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | F | — | — |
| 2023-11-21 | Vered Bisker-Leib | Chief Operating Officer | F | — | — |
| 2023-04-24 | RICHARD S LINDAHL | Director | A | — | — |
| 2023-03-10 | Thomas J. Schuetz | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 15,219,994 | — |
| — | Director | 15,219,994 | — |
| — | Director | 15,219,994 | — |
| — | Director | 14,510,319 | — |
| — | CHIEF EXECUTIVE OFFICER | 6,603,336 | — |
| — | Director | 3,571,428 | — |
| — | CHIEF EXECUTIVE OFFICER | 3,124,426 | — |
| — | Director | 1,791,549 | — |
| — | CFO | 525,000 | — |
| — | Chief Accounting Officer | 397,500 | — |
| — | General Counsel | 196,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CMPX quote page; the site-wide leaderboard is on the insider transactions hub.